A comprehensive analysis of 12 thrombophilic mutations and related parameters in patients with inflammatory bowel disease: Data from Turkey

Journal of Thrombosis and Thrombolysis

Volumn 22, Issue 3, 2006, Pages 205-212

  Yılmaz, Şerif ^a   Bayan, Kadim ^a   Tüzün, Yekta ^a   Batun, Sabri ^a   Altıntaş, Abdullah ^a  

^a DICLE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Inflammatory bowel disease; Thrombophilic mutations

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTITHROMBIN III; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN B100; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; DIPEPTIDYL CARBOXYPEPTIDASE; FIBRINOGEN; FIBRINOGEN B BETA CHAIN; GLYCOPROTEIN IIIA; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTEIN S; PROTHROMBIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; ENTERITIS; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; HUMAN; HYPERCOAGULABILITY; MALE; PATHOGENESIS; PRIORITY JOURNAL; THROMBOPHILIA; TURKEY (REPUBLIC);

EID: 33845252483     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-006-9032-5     Document Type: Article

References (50)

1. Bernstein CN, Blanchard JF, Houston D et al (2001) The incidence of venous thromboembolic disease among patients with IBD: A population-based study. Thromb Haemost 85:430-434
2. Talbot RW, Heppell J, Dozois RR et al (1986) Vascular complications of inflammatory bowel disease. Mayo Clin Proc 61:140-145
3. Dhillon AP, Anthony A, Sim R et al (1992) Mucosal capillary thrombi in rectal biopsies. Histopathology 21:127-133
4. Wakefield AJ, Sawyer AM, Hudson M et al (1991) Smoking, the oral contraceptive pill and Crohn's disease. Dig Dis Sci 36:1147-1150
5. Logan RFA, Kay CR (1989) Oral contraception, smoking and inflammatory bowel disease findings in the Royal College of General Practitioners oral contraceptive study. Int J Epidemiol 18:105-107
6. Thompson N, Wakefield AJ, Pounder RE (1995) Inherited disorders of coagulation appear to protect against inflammatory bowel disease. Gastroenterology 108:1011-1015
7. Crowther MA, Kelton JG (2003) Congenital thrombophilic states associated with venous thrombosis: A qualitative overview and proposed classification system. Ann Intern Med 138(2):128-134
8. Martinelli I (2001) Risk factors in venous thromboembolism. Thromb Haemost 86(1):395-403
9. Harvey R, Bradshaw J (1980) A simple index of Crohn's disease activity. Lancet 1:514
10. Truelove S, Witts L (1955) Cortisone in ulcerative colitis. Br Med J 2:1041-1048
11. Kirsner JB, Spencer JA (1963) Family occurrences of ulcerative colitis, regional enteritis, and ileocolitis. Ann Intern Med 59:133-144
12. Papa A, Danese S, Grillo A et al (2003) Review article: Inherited thrombophilia in inflammatory bowel disease. Am J Gastroenterol 98(6):1247-1251
13. Wakefield AJ, Sawyerr AM, Dhillon AP et al (1989) Pathogenesis of Crohn's disease: Multifocal gastrointestinal infarction. Lancet 2(8671):1057-1062
14. Jackson LM, O'Gorman PJ, O'Connell J et al (1997) Thrombosis in inflammatory bowel disease: Clinical setting, procoagulant profile and factor V Leiden. QJM 90(3):183-188
15. Donmez Y, Kanadasi M, Tanriverdi K et al (2004) Prothrombin 20210GA and factor V Leiden mutations in patients less than 55 years old with myocardial infarction. Jpn Heart J 45(3):505-512
16. Castoldi E, Rosing J. Factor V (2004) Leiden: A disorder of factor V anticoagulant function. Curr Opin Hematol 11(3):176-181
17. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM et al (1995) Enhancement by factor V Leiden mutation of risk of deep vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 346:1593-1596
18. Rosendaal FR, Koster T, Vandenbroucke JP et al (1995) High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 86:4700-4702
19. Haslam N, Standen GR, Probert GS (1999) An investigation of the association of the factor V Leiden mutation and inflammatory bowel disease. Eur J Gastroenterol Hepatol 11:1289-1291
20. Over HH, Ulgen S, Tuglular T et al (1998) Thrombophilia and inflammatory bowel disease: Does factor V mutation have a role? Eur J Gastroenterol Hepatol 10:827-829
21. Haslam N, Standen GR, Probert CS (2001) An investigation of the association of the prothrombin G20210A gene mutation and inflammatory bowel disease: Factor II and IBD. Inflamm Bowel Dis 7:133-135
22. Papa A, Stefano V, Gasbarrini A et al (2000) Prevalence of factor V Leiden and the G20210A prothrombin-gene mutation in inflammatory bowel disease. Blood Coagul Fibrinolysis 11:499-503
23. Bernardi F, Faioni EM, Castoldi E et al (1997) A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood 90:1552-1557
24. Mikkola H, Syrjala M, Rasi V et al (1994) Deficiency in the A-subunit of coagulation factor XIII: Two novel point mutations demonstrate different effects on transcript levels. Blood 84(2):517-525
25. Saibeni S, Vecchi M, Faioni EM et al (2003) Val34Leu factor XIII polymorphism in Italian patients with inflammatory bowel disease. Dig Liver Dis 35(1):32-36
26. Dong QL, Zhang C (2004) Association between the polymorphism of beta-fibrinogen gene-455G/A and ischemic stroke. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 21(3):274-276
27. Humphries S, Henry J, Montgomery H (1999) Gene-environment interaction in the determination of levels of haemostatic variables involved in thrombosis and fibrinolysis. Blood Coagul Fibrinolysis 10:S17-S21
28. Eriksson P, Kallin B, Van't Hooft FM et al (1995) Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 92:1851-1855
29. Tassies D, Espinosa G, Munoz-Rodriguez FJ et al (2000) The 4G/5G polymorphism of the type 1 plasminogen activator inhibitor gene and thrombosis in patients with antiphospholipid syndrome. Arthritis Rheum 43: 2349-2358
30. Stegnar M, Uhrin P, Peternel P et al (1998) The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: Relationship to plasma PAI-1 level in venous thromboembolism. Thromb Haemost 79: 975-979
31. Dossenbach-Glaninger A, van Trotsenburg M, Dossenbach M et al (2003) Plasminogen activator inhibitor 1 4G/5G polymorphism and coagulation factor XIII Val34Leu polymorphism: Impaired fibrinolysis and early pregnancy loss. Clin Chem 49(7):1081-1086
32. Segui R, Estelles A, Mira Y et al (2000) PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects. Br J Haematol 111(1):122-128
33. Hefler L, Jirecek S, Heim K et al (2004) Genetic polymorphisms associated with thrombophilia and vascular disease in women with unexplained late intrauterine fetal death: A multicenter study. J Soc Gynecol Investig 11(1):42-44
34. Sans M, Tassies D, Pellise M et al (2003) The 4G/4G genotype of the 4G/ 5G polymorphism of the type-1 plasminogen activator inhibitor (PAI-1) gene is a determinant of penetrating behaviour in patients with Crohn's disease. Aliment Pharmacol Ther 17(8):1039-1047
35. Slowik A, Dziedzic T, Turaj W et al (2004) A2 alelle of GpIIIa gene is a risk factor for stroke caused by large-vessel disease in males. Stroke 35(7):1589-1593
36. den Heijer M, Koster T, Blom HJ et al (1996) Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 334:759-762
37. Morgenstern I, Raimakers MTM, Peters WHM et al (2003) Homocysteine, cysteine and glutathione in human colonic mucosa: Elevated levels of homocysteine in patients with inflammatory bowel disease. Dig Dis Sci 48:2083-2090
38. van der Put NM, Gabreels F, Stevens EM et al (1998) A second common mutation in the methylenetetrahydrofolate reductase gene: An additional risk factor for neuraltube defects? Am J Hum Genet 62:1044-1051
39. Weisberg I, Tran P, Christensen B et al (1998) A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 64:169-172
40. Hanson NQ, Aras O, Yang F et al (2001) C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase gene: Incidence and effect of combined genotypes on plasma fasting and post-methionine load homocysteine in vascular disease. Clin Chem 47(4):661-666
41. Oldenburg B, Fijnheer R, van der Griend R et al (2000) Homocysteine in inflammatory bowel disease: A risk factor for thromboembolic complications? Am J Gastroenterol 95(10):2825-2830
42. Brown NJ, Vaughan DE (2000) Prothrombotic effects of angiotensin. Adv Intern Med 45:419-429
43. Rigat B, Hubert C, Alhenc-Gelas MF et al (1990) An insertion/deletion polymorphism in the angiotensin converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86:1343-1346
44. Butler R, Morris AD, Burchell B et al (1999) DD angiotensin-converting enzyme gene polymorphism is associated with endothelial dysfunction in normal humans. Hypertension 33:1164-1168
45. Bedir A, Arik N, Adam B et al (1999) Angiotensin converting enzyme gene polymorphism and activity in Turkish patients with essential hypertension. Am J Hypertens 12:1038-1043
46. Brown MS, Goldstein JL (1986) A receptor mediated pathway for cholesterol homeostasis. Science 232:34-47
47. Tybjaerg-Hansen A, Steffensen R, Meinertz H et al (1998) Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease. N Engl J Med 338:1577-1584
48. Miller J (1990) Dyslipoproteinaemia of liver disease. Bailliers Clin Endocrinol Metab 4:807-832
49. Belo L, Gaffney D, Caslake M et al (2004) Apolipoprotein E and cholesteryl ester transfer protein polymorphisms in normal and preeclamptic pregnancies. Eur J Obstet Gynecol Reprod Biol 112(1):9-15
50. Scuteri A, Bos AJ, Zonderman AB et al (2001) Is the apoE4 allele an independent predictor of coronary events? Am J Med 110(1):28-32